Akebia Therapeutics (AKBA) Net Margin (2017 - 2026)

Akebia Therapeutics (AKBA) has 10 years of Net Margin data on file, last reported at 16.91% in Q1 2026.

• On a quarterly basis, Net Margin fell 2757.0% year-over-year to 16.91% in Q1 2026; TTM through Mar 2026 was 8.83%, a 1568.0% increase from a year earlier, with the FY2025 full-year figure at 2.26%, up 4107.0% from the prior year.
• Net Margin for Q1 2026 stood at 16.91%, up from 21.25% in the prior quarter.
• Over the last five years, Net Margin for AKBA reached as high as 23.3% in Q2 2022 and fell as low as 83564.47% in Q1 2022.
• Historically, Net Margin has averaged 4940.21% across 5 years, with a median of 19.82% in 2023.
• Across the five-year window, Net Margin tumbled 8343516 bps in 2022 and surged 8349729 bps in 2023, its largest moves.
• Year by year, Net Margin stood at 7.39% in 2022, then soared by 115 bps to 1.09% in 2023, then plunged by 4589 bps to 49.04% in 2024, then jumped by 57 bps to 21.25% in 2025, then advanced by 20 bps to 16.91% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 16.91% in Q1 2026, 21.25% in Q4 2025, and 0.92% in Q3 2025.